Philadelphia University + Thomas Jefferson University

Harshyne, Larry A.

< Back


Larry A Harshyne Jr

Larry A. Harshyne, PhD

Contact Dr. Harshyne

900 Walnut Street
JHN 4th floor
Philadelphia, PA 19107

(215) 503-9893
(215) 503-4358 fax

Expertise and Research Interests

My research interests include various interactions between gliomas and the immune system. We are currently developing a dendritic cell-based vaccine for therapy of gliomas. Dendritic cells play an instrumental role in initiating and orchestrating immune responses within the body. Dendritic cells are located through out the body where they sample the local environment for traces of pathogens or tumors. Pieces of tumors are engulfed by dendritic cells that then migrate to draining lymph nodes. Here, dendritic cells activate lymphocytes. Activated lymphocytes then enter the circulation and attack infected or malignant cells. Tumors, on the other hand, have evolved many ways to evade detection by the immune system and to actively suppress anti-tumor immune responses. Our vaccine attempts to circumvent these evasive tricks utilized by gliomas by feeding dendritic cells pieces of dead and dying tumor cells in a culture dish. These loaded-dendritic cells are then injected back into patients to assume their natural role. Dendritic cell vaccination provides a boost for the immune system in hopes of preventing tumors recurrence.


Most Recent Peer-Reviewed Publications

  1. Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer
  2. Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes
  3. Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes
  4. Human parechovirus and enterovirus initiate distinct CNS innate immune responses: Pathogenic and diagnostic implications
  5. Immune biomarkers of treatment failure for a patient on a phase i clinical trial of pembrolizumab plus radiotherapy
  6. Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients
  7. Enhancement of glioma-specific immunity in mice by “NOBEL”, an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide
  8. Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm
  9. The somatic genomic landscape of glioblastoma
  10. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers
  11. c-Jun NH2-terminal kinase 2α2 promotes the tumorigenicity of human glioblastoma cells
  12. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells
  13. A role for class A scavenger receptor in dendritic cell nibbling from live cells
  14. Novel Training Concepts and Techniques Used to Increase Safety Awareness in the Laboratory Animal Facility
  15. Changes in dendritic cell migration and activation during SIV infection suggest a role in initial viral spread and eventual immunosuppression
  16. Erratum: Dendritic cells acquire antigens from live cells for cross-presentation to CTL. (The Journal of Immunology (2001) 166 (3717-3723))
  17. Dendritic cells acquire antigens from live cells for cross-presentation to CTL
  18. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: Implications for dendritic cell-based vaccines